Patients with nonsquamous NSCLC ( stage IIIB/IV or recurrent ) and no prior systemic therapy for advanced disease were randomized to IV carboplatin ( AUC , 6 mg/ml min ) and paclitaxel ( 200 mg/m2 ) for up to six 3-week cycles , plus either oral motesanib 125 mg q.d. or placebo .